Focal HIFU Ablation of Prostate Cancer Using Advanced Ultrasound Guidance

使用先进超声引导进行前列腺癌局灶 HIFU 消融

• 批准号: 7893335
• 负责人: Ernest Joseph Feleppa
• 金额: $ 58.1万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-03 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7893335
• 关键词: 3-Dimensional; Ablation; Achievement; Address; Adverse effects; Biopsy; Brachytherapy; Cancerous; Classification; Clinical; Clinical Data; Cold Therapy; Computer software; Core Biopsy; Country; Cryosurgery; Data; Databases; Detection; Developed Countries; Development; Diagnostic; Dose; England; Excision; External Beam Radiation Therapy; Focused Ultrasound Therapy; Gland; Gold; Histocompatibility Testing; Histologic; Histology; Hospitals; Image; Image Guided Biopsy; Impotence; Investigation; Lesion; Location; London; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of prostate; Marketing; Medical center; Methods; Modality; NIH Program Announcements; Nerve; Operative Surgical Procedures; Patients; Procedures; Prostate; Prostatic Diseases; Radiation; Radiation therapy; Rectal Fistula; Recurrence; Research; Research Institute; Salvage Therapy; Shapes; Spatial Distribution; Spectrum Analysis; System; Therapeutic; Time; Tissues; Ultrasonic Therapy; Ultrasonics; Ultrasonography; United States; United States National Institutes of Health; Universities; Urethral Obstruction; Urinary Incontinence; Validation; Virginia; base; cancer imaging; cancer therapy; college; cost; experience; high risk; imaging modality; improved; in vivo; instrument; men; novel strategies; prototype; public health relevance; quantum

DESCRIPTION (provided by applicant): Riverside Research Institute (RRI) and Focus Surgery, Inc. (FSI) propose an Academic-Industrial Partnership to develop and evaluate advanced ultrasonic means of guiding biopsies and treatment of prostate cancer, particularly treatment using focused ablative ultrasonic therapy. The proposed approach represents a very significant advancement in detection and treatment for this very common cancer of men in the United States and other developed countries worldwide. The proposed RRI-FSI Partnership specifically addresses NIH Program Announcement PAR-07-214, "Development and Validation of In-vivo Imaging Systems and Methods for Cancer Investigations." We seek to integrate advanced ultrasonic means of imaging prostate cancer that have been developed by RRI with a proven ultrasonic instrument that has been developed and manufactured by FSI for ablative treatment of prostate cancer. Conventional imaging methods cannot distinguish cancerous from non-cancerous prostate tissue, and consequently, all current biopsy and treatment methods essentially involve the entire gland. By emphasizing combined ultrasonic means of imaging cancer and treating it, we will overcome current imaging limitations, obviating the current need to ablate all tissue in the gland, and enabling treatment to be targeted to image cancerous tissue. This elegant integration of ultrasonic imaging and treatment modalities represents a novel approach to more-effectively treating only cancerous tissue in the prostate while reducing adverse side effects. By providing an effective means of delivering focal treatment, the proposed methods represent a quantum step forward in prostate-cancer management. The significance of these methods extends to biopsy guidance in general and to focal treatments of any type, including surgery, cryoablation, and radiation therapy. The proposed studies consist of three component efforts: 1) expanding our existing prostate-tissue data base and refining our tissue classification methods using transrectal 12-core biopsy histology gold standards; 2) evaluating targeting efficacy using transperineal template-guided saturation-biopsy histology gold standards; and 3) developing methods to identify viable cancer regions in radiation-treated patients who require salvage therapy. The proposed RRI-FSI Partnership will include internationally respected clinical collaborators who are experienced in the use of RRI's tissue-type imaging methods and FSI's ultrasonic ablation instrument. Our clinical collaborators are affiliated with the Virginia Mason Medical Center in Seattle, WA and the University College London Hospitals in London, England. PUBLIC HEALTH RELEVANCE: Riverside Research Institute and Focus Surgery, Inc. propose an Academic-Industrial Partnership to develop and evaluate advanced ultrasonic means of guiding prostate-cancer biopsies and treatment, particularly ablative ultrasonic therapy. The proposed approach represents a very significant advance in detection and therapy for this very common cancer of men in the United States and developed countries worldwide.

描述(由申请人提供)：Riverside Research Institute(RRI)和Focus Surgery，Inc.(FSI)提议建立一个学术-产业合作伙伴关系，以开发和评估先进的超声手段来指导前列腺癌的活检和治疗，特别是使用聚焦消融超声疗法的治疗。拟议的方法代表着在检测和治疗这种在美国和世界其他发达国家非常常见的男性癌症方面取得了非常重大的进步。建议的RRI-FSI伙伴关系特别涉及NIH项目公告PAR-07-214，“癌症研究体内成像系统和方法的开发和验证”。我们寻求将RRI开发的先进的前列腺癌成像超声手段与FSI开发和制造的用于前列腺癌消融治疗的成熟超声仪器相结合。传统的成像方法不能区分前列腺癌和非癌组织，因此，目前所有的活检和治疗方法基本上都涉及整个腺体。通过强调联合超声手段对癌症的成像和治疗，我们将克服目前成像的局限性，消除目前需要消融所有腺体组织的需要，并使治疗能够针对肿瘤组织进行成像。这种超声成像和治疗方式的完美结合代表了一种新的方法，可以更有效地仅治疗前列腺癌组织，同时减少副作用。通过提供一种提供局部治疗的有效手段，建议的方法代表着前列腺癌管理方面的一大进步。这些方法的意义一般扩展到活检指导和任何类型的局灶性治疗，包括手术、冷冻消融和放射治疗。拟议的研究包括三个部分：1)扩展我们现有的前列腺组织数据库，并使用经直肠12核心活检组织学金标准改进我们的组织分类方法；2)使用经会阴模板引导的饱和活检组织学金标准评估靶向疗效；以及3)开发方法，以确定需要挽救治疗的放射治疗患者的可存活癌症区域。建议的RRI-FSI伙伴关系将包括在使用RRI的组织类型成像方法和FSI的超声波消融仪器方面经验丰富的国际知名临床合作者。我们的临床合作者隶属于华盛顿州西雅图的弗吉尼亚梅森医疗中心和英国伦敦的伦敦大学学院医院。 公共卫生相关性：Riverside Research Institute和Focus Surgery，Inc.提出了一个学术-产业合作伙伴关系，以开发和评估指导前列腺癌活检和治疗的先进超声手段，特别是消融性超声波治疗。建议的方法代表着在检测和治疗这种在美国和世界各地发达国家非常常见的男性癌症方面取得了非常重大的进步。